Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093846 · ClinicalTrials.gov registry record · Phase 3
38 Week Extension Study to CAIN457C2303
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT01093846 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 59 participants.
The verdict
NCT01093846, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy
Interventions
- DRUG AIN457
- DRUG Placebo AIN457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093846
The ClinicalTrials.gov registry entry for NCT01093846 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AIN457 is the first listed.
NCT01093846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093846 about?
NCT01093846 is a clinical study titled "38 Week Extension Study to CAIN457C2303". A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy
What is the current status of trial NCT01093846?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2010-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01093846?
The interventions under investigation include: AIN457 (DRUG), Placebo AIN457 (DRUG).
Who is sponsoring clinical trial NCT01093846?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.